Background We performed a systematic literature review to identify the most recently
published randomized controlled trials (RCTs) in multiple myeloma (MM) with a patient …

Substantial improvements in survival have been seen in multiple myeloma (MM) over recent
years, associated with the introduction and widespread use of multiple novel agents and …

Simple Summary It is recognized that patients with multiple myeloma (MM) experience a
high burden of disease and treatment-related symptoms that impact upon their quality of life …

Simple Summary In multiple myeloma, a type of blood cancer, the measurement of the
outcomes of treatment reported by patients (patient-reported outcome measurement) is …

Background The introduction of novel agents has contributed to improvements in survival in
multiple myeloma (MM), and, based on phase 3 investigations, multiple novel regimens …

Purpose We performed a systematic review to quantify the amount of evidence-based data
available on patient-reported outcomes (PRO) in Relapsed/Refractory Multiple Myeloma …

Objectives Patients with multiple myeloma (MM) enrolled in randomized control trials (RCTs)
discontinue treatment for various reasons; however, no prior study has analyzed reasons for …

Poorva Bindal a, Mimi Najjar b, Kelly Koehn c, Amandeep Godara d, douglas W Sborov d,
Brian McClune d, Kelley Jullian d, Charlotte Wagner d and Ghulam rehman Mohyuddin d …

e18615 Background: It is recommended to include patient-reported outcomes (PROs) in
cancer trials to ensure clinical benefit based on patients' perceptions. For multiple myeloma …

Importance A thorough understanding of the optimal role and sequence of agents for
treatment of multiple myeloma (MM) requires knowledge of the use and rate of postprotocol …